Egetis Therapeutics Future Growth
Future criteria checks 6/6
Egetis Therapeutics is forecast to grow earnings and revenue by 85.4% and 67.1% per annum respectively. EPS is expected to grow by 87.7% per annum. Return on equity is forecast to be 38.5% in 3 years.
Key information
85.4%
Earnings growth rate
87.7%
EPS growth rate
| Biotechs earnings growth | 31.1% |
| Revenue growth rate | 67.1% |
| Future return on equity | 38.5% |
| Analyst coverage | Low |
| Last updated | 22 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 648 | 297 | N/A | 297 | 1 |
| 12/31/2025 | 471 | 105 | -19 | 86 | 4 |
| 12/31/2024 | 65 | -291 | -312 | -285 | 2 |
| 12/31/2023 | 58 | -327 | -278 | -278 | N/A |
| 9/30/2023 | 31 | -319 | -299 | -299 | N/A |
| 6/30/2023 | 24 | -286 | -249 | -249 | N/A |
| 3/31/2023 | 22 | -240 | -220 | -220 | N/A |
| 12/31/2022 | 23 | -194 | -173 | -173 | N/A |
| 9/30/2022 | 20 | -148 | -137 | -137 | N/A |
| 6/30/2022 | 21 | -113 | -125 | -125 | N/A |
| 3/31/2022 | 42 | -114 | -128 | -128 | N/A |
| 12/31/2021 | 38 | -104 | -130 | -130 | N/A |
| 9/30/2021 | 40 | -147 | -143 | -143 | N/A |
| 6/30/2021 | 36 | -153 | -137 | -137 | N/A |
| 3/31/2021 | 33 | -155 | -133 | -133 | N/A |
| 12/31/2020 | 41 | -178 | -135 | -135 | N/A |
| 9/30/2020 | 53 | -127 | -124 | -124 | N/A |
| 6/30/2020 | 56 | -134 | -134 | -134 | N/A |
| 3/31/2020 | 39 | -127 | -127 | -127 | N/A |
| 12/31/2019 | 83 | -61 | -63 | -63 | N/A |
| 9/30/2019 | 77 | -61 | -54 | -54 | N/A |
| 6/30/2019 | 77 | -48 | -38 | -38 | N/A |
| 3/31/2019 | 82 | -46 | -39 | -39 | N/A |
| 12/31/2018 | 28 | -85 | -81 | -81 | N/A |
| 9/30/2018 | 31 | -95 | -106 | -106 | N/A |
| 6/30/2018 | 24 | -103 | -97 | -97 | N/A |
| 3/31/2018 | 14 | -91 | -90 | -90 | N/A |
| 12/31/2017 | 14 | -88 | -87 | -87 | N/A |
| 9/30/2017 | N/A | -67 | N/A | -51 | N/A |
| 6/30/2017 | 0 | -48 | N/A | -49 | N/A |
| 3/31/2017 | N/A | -44 | N/A | -41 | N/A |
| 12/31/2016 | N/A | -38 | N/A | -36 | N/A |
| 9/30/2016 | N/A | -36 | N/A | -36 | N/A |
| 6/30/2016 | N/A | -39 | N/A | -38 | N/A |
| 3/31/2016 | N/A | -39 | N/A | -44 | N/A |
| 12/31/2015 | N/A | -44 | N/A | -51 | N/A |
| 9/30/2015 | N/A | -53 | N/A | -55 | N/A |
| 6/30/2015 | N/A | -53 | N/A | -52 | N/A |
| 3/31/2015 | N/A | -54 | N/A | -47 | N/A |
| 12/31/2014 | N/A | -48 | N/A | -41 | N/A |
| 9/30/2014 | N/A | -38 | N/A | -34 | N/A |
| 6/30/2014 | N/A | -31 | N/A | -31 | N/A |
| 3/31/2014 | N/A | -24 | N/A | -25 | N/A |
| 12/31/2013 | N/A | -26 | N/A | -28 | N/A |
| 9/30/2013 | N/A | -27 | N/A | -29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: P0F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: P0F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: P0F is expected to become profitable in the next 3 years.
Revenue vs Market: P0F's revenue (67.1% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: P0F's revenue (67.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: P0F's Return on Equity is forecast to be high in 3 years time (38.5%)